Julphar delivers continued strong performance in Q2 H1 driven by revenue growth margin expansion and accelerated deleveraging

Julphar achieved solid growth and notable progress in Q2, recording net revenue of mAED 348.1, a 3.0% increase lifted H1 net revenue to mAED 707.3, reflecting a 4.7% growth (5.8% growth at constant rate), and boosted EBITDA by mAED 138.5 in H1, rising from mAED 99.7 to mAED 238.2.

13^th August 2025, Ras Al Khaimah, UAE: Gulf Pharmaceutical Industries (Julphar), a leading pharmaceutical powerhouse in the MENA region, today announced its financial results for the second quarter and first half of the year. The results reflect steady top-line growth, robust EBITDA expansion, strong profitability from continued operations, and significantly strengthened balance sheet.

The company delivered improved core operating margins from continued operations, achieving a gross profit of mAED 298.0 at 42.1% and growing by 12.8%. EBITDA grew by 27.9% and reached mAED 91.6 with the margin rising to 13.0% from 10.6%. Operating income grew to mAED 58.0 from mAED 38.2, while net income jumped to mAED 38.6 from mAED 7.3 an increase of mAED 31.3 compared to the same period last year.Total net profit reached mAED 158.2 including mAED 118.7 one-off net capital gain from the divestment of Zahrat Al Rawdah Pharmacies LLC.

Additionally, the Group cemented its cash position, generating mAED 42.4 in cash flow from continued operations, reflecting solid business performance and sustained financial discipline. Total loans and other interest-bearing debt were reduced by mAED 527.5 driving a sharp improvement in the Net Debt-to-EBITDA ratio from 10.7x to 1.2x — making a transformational boost in company’s financial standing. Shareholders’ equity also increased from mAED 809.6 in December 2024 to mAED 967.1 in the first half, reflecting a strengthened balance sheet, higher profitability, and increased financial flexibility to fuel future growth.

In the first half of the year, Julphar strengthened its market presence and portfolio by launching 11 new products including 3 insulin analogues in UAE, obtaining 19 additional regulatory approvals, and expanding its marketed portfolio. The Company also advanced promising pipeline opportunities and boosted its R&D capabilities, aligning with its strategic priorities and leveraging core strengths to drive sustainable growth.

Julphar continues to integrate operational excellence and disciplined capital allocation within a resilient framework that maintains flexibility. The company remains dedicated to driving growth by expanding its presence in core markets — including manufacturing infrastructure in KSA — and investing in high-value, differentiated products, supported by strategic portfolio optimization and underpinned by solid financial discipline.

Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, Julphar, said: " Julphar’s performance in the opening six months of 2025 marks a pivotal step forward, with strong revenue growth and continued progress across our strategic priorities. These results reflect our commitment to operational excellence and our team’s ability to achieve ambitious goals. With new product launches and market expansion, we are well-positioned to strengthen our role as a leading healthcare partner across the GCC and beyond.”

Basel Ziyadeh, Chief Executive Officer, Julphar, added: “Julphar’s resilient first-half performance highlights the robustness of its core business, supported by the breadth and depth of our capabilities. Our ongoing optimization initiatives are strategically redirecting investments and resources from mature segments toward high-potential growth drivers, advancing our pipeline in growing therapeutic areas, focusing on quality manufacturing and fueling sustainable growth”.

-Ends-